IQVIA Holdings Inc. (IQV) Stock

Understand IQVIA Holdings Inc.: how it makes money

IQVIA runs clinical trials and sells data analytics and software to pharmaceutical and biotech companies, earning fees per study and recurring subscription revenue. Over half its revenue comes from R&D services tied to the global drug-development pipeline, with the rest from commercial intelligence and technology platforms.

Every new drug must pass through clinical trials before launch, and IQVIA has become the default infrastructure layer across that pipeline, so its revenue grows with the number of trials and launches initiated rather than with the price of any single molecule.

Business quality (Mixed): An 18% return on equity shows the model compounds, but a 12.4% operating margin with meaningful pass-through revenue means profit growth tracks trial volumes more than software-style pricing, capping how high the multiple can sustainably run.

Valuation: Trades at 39× trailing earnings · $43.4B market cap.

Bull case

• Drug launch wave accelerating: Management cited a 45% increase in new drug launches lifting commercial demand, which pulls more pharma and biotech sponsors into R&D Solutions ($2.4B, 57% of revenue) and lengthens each client relationship through launch and post-market evidence phases.
• Structural outsourcing tailwind intact: Management framed emerging biopharma expansion as a structural outsourcing opportunity and noted that R&D demand indicators have improved with shortening decision timelines, meaning sponsors are committing to outsourced trial execution on faster clocks and reducing the传统的 lag between RFP and first billable month.

Bear case

• Pass-through caps margin expansion: Management confirmed that pass-through revenue generates no profit, keeping operating margin near 12% and meaning trial-volume growth lifts the top line without a proportional earnings bump, so margin leverage only arrives if pass-through share shrinks over time.
• Stale trials lurk in backlog: Management disclosed it is reviewing potentially inactive trials within the contracted backlog, a flag that a portion of accumulated work may never bill and could create a revenue step-down in R&D Solutions if studies are shelved or cancelled.
• Premium multiple on modest growth: At a P/E of 38.8x the stock embeds well above the 8% revenue growth rate, yet the 12% operating margin and pass-through dynamics limit how quickly earnings can close that gap, leaving little cushion for execution slippage or a trial-pipeline downturn.

Related Companies (Business Services; 8 comparable business services companies)

• Charles River Laboratories International, Inc. (CRL)
• Medpace Holdings, Inc. (MEDP)
• Incyte Corporation (INCY)
• UL Solutions Inc. (ULS)
• Aecom (ACM)
• United Rentals, Inc. (URI)
• Omnicom Group Inc. (OMC)
• S&P Global Inc. (SPGI)